Latest Ratios: P/E Ratio -0.6x · EV/EBITDA N/A · ROE -291.6%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $4M | $7M | $6.3B | $13.7B | $49.5B | $25.2B | $22.0B | $11.8B | $33.3B | — |
| Enterprise Value | $3M | $3M | $4M | $6.3B | $13.7B | $49.5B | $25.2B | $22.0B | $11.8B | $33.3B | — |
| P/E Ratio → | -0.55 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | 1915331.63 | 94701.98 | — |
| P/B Ratio | 1.72 | 1.58 | 2.74 | 1119.73 | 1908.36 | 4594.02 | 3513.55 | 4631.69 | 1892.58 | 6312.08 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | 1914283.47 | 94686.05 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | 100.0% | 50.9% | 54.3% |
| Operating Margin | — | — | — | — | — | — | — | — | -146080.5% | -1315.6% | -347.5% |
| Net Profit Margin | — | — | — | — | — | — | — | — | -158669.6% | -1529.2% | -538.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -291.6% | -291.6% | -280.0% | -156.4% | -146.5% | -125.1% | -196.6% | -241.7% | -170.0% | -245.4% | — |
| ROA | -169.2% | -169.2% | -205.4% | -125.5% | -119.0% | -103.8% | -147.1% | -184.8% | -146.8% | -162.6% | -567.9% |
| ROIC | -453.7% | -453.7% | -517.6% | -259.5% | -396.2% | -609.4% | -24273.5% | — | — | — | -1887.0% |
| ROCE | -165.8% | -165.8% | -223.1% | -156.8% | -139.2% | -120.3% | -178.6% | -191.0% | -156.5% | -211.2% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | 0.23 | 0.07 | 0.08 | 0.07 | 0.11 | 0.16 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.12 | -1.03 | -0.43 | -0.60 | -0.80 | -0.90 | -1.13 | -1.04 | -1.06 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -611.04 | — | -49.45 | -4.65 | -12.43 | — | — |
Net cash position: cash ($762365) exceeds total debt ($492352)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.29 | 1.29 | 5.67 | 3.36 | 5.00 | 7.83 | 8.32 | 3.15 | 7.13 | 6.93 | 0.14 |
| Quick Ratio | 1.29 | 1.29 | 5.67 | 3.36 | 3.45 | 7.00 | 7.72 | 3.10 | 7.07 | 6.71 | 0.11 |
| Cash Ratio | 1.02 | 1.02 | 5.34 | 3.14 | 2.87 | 6.13 | 7.33 | 2.98 | 6.64 | 6.60 | 0.10 |
| Asset Turnover | — | — | — | — | — | — | — | — | 0.00 | 0.06 | 1.05 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 0.90 | 5.88 |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | 7.11 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $787020 | $1M | $2M | $2M | $2M | $959611 | $374999 | $225243 | $195751 | $195351 |
Imminent liquidity and dilution
Based on reported figures, NDRA trades at a price-to-book ratio of 1.74, which, when viewed alongside a negative TTM P/E of -0.56, suggests the market is pricing the firm as a distressed option rather than a traditional growth-stage medical technology entity with established commercial prospects.
The lack of meaningful revenue multiples like P/S highlights the market's skepticism regarding the company's ability to transition from a developmental R&D firm to a commercial entity. Investors should monitor whether the current valuation floor holds as the company approaches critical clinical data milestones, as any further dilution will likely compress these multiples significantly.
As reported in financial statements, the company's ROIC has consistently remained in deep negative territory, reaching -84.0% in 2026Q1, which indicates that the firm is currently destroying shareholder capital rather than compounding it through its ongoing investment in the TAEUS platform and regulatory pathways.
The persistent decay in ROIC is a direct consequence of high fixed-cost R&D spending without any offsetting revenue generation. This trend suggests that the company's current capital allocation strategy is unsustainable without a fundamental shift toward commercialization or a strategic partnership that provides non-dilutive funding.
According to recent SEC filings, the company's current ratio has deteriorated to 0.64 as of 2026Q1, a level that signals severe liquidity stress and suggests that the firm may struggle to meet its short-term obligations without immediate access to additional external capital or financing.
The decline in the quick ratio to parity with the current ratio confirms that the company lacks meaningful inventory or liquid assets to buffer against operational shocks. This vulnerability warrants close monitoring, as the current cash runway appears insufficient to support the company's clinical trial and regulatory roadmap through the next fiscal year.
Investors frequently misapply traditional growth metrics like PEG or P/E to NDRA, which obscures the reality that the company is a pre-revenue developmental firm where the primary value driver is regulatory and clinical validation rather than current earnings or historical growth rates.
Using earnings-based multiples for a company with no revenue is fundamentally flawed and leads to misleading conclusions about the firm's intrinsic value. Analysts should instead focus on the cash burn rate relative to the timeline for FDA milestones, as this provides a more accurate assessment of the company's survival probability and potential for future dilution.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NDRA stock.
ENDRA Life Sciences Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
ENDRA Life Sciences Inc.'s return on equity (ROE) is -291.6%. The historical average is -221.4%.
Based on historical data, ENDRA Life Sciences Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.